



Advent France Biotechnology

Press release

Anne Horgan joins Advent France Biotechnology as Partner and Arnaud Foussat as Operating Partner

Paris, France, September 12, 2017 – Advent France Biotechnology announced today two new appointments to strengthen its team. Anne Horgan is joining the company as Partner and Arnaud Foussat as Operating Partner, a few months after the launch of its first seed fund dedicated to the Life Sciences.

Anne Horgan, 41, graduated from the Institut National des Sciences Appliquées de Rouen (French National Institute of Applied Sciences) specialising in chemistry, she holds a PhD in organic chemistry from the University of Bristol and completed her post-doctoral research at Yale University.

In 2003, Anne began her career as a medicinal chemist at Cambridge Biotechnology Ltd, where she worked on preclinical programs in pain and obesity. In 2007, she joined Cancer Research Technology Ltd, the technology transfer arm of Cancer Research UK, Britain's largest research charity exclusively dedicated to the fight against cancer, where she was involved in the identification, evaluation, protection, development and commercialisation of intellectual property stemming from academic research funded by Cancer Research UK. Anne joined French venture capital firm Sofinnova Partners in 2013, where she was involved in biopharmaceutical investments as a Senior Associate.

Arnaud Foussat, 44, graduated from the Institut Pasteur, and holds a PhD in Immunology from the Université Paris-Diderot (Paris VII) and completed his post-doctoral research at INSERM (National institute of science and medical research).

Arnaud started his career in 2004 at TxCell, a French biotechnology company specialised in cell therapy. In 2005 he was appointed Head of Research and Development and became Chief Scientific Officer in 2015, a role in which he supervised innovation, intellectual property and the search for public financing, while managing academic and pharmaceutical partnerships. In 2016, Arnaud was promoted to Senior Vice-President, Corporate Development, Head of Scientific Collaboration and Alliances at TxCell. In early 2017, Arnaud founded Four Seasons Park, his own consulting firm dedicated to supporting Life Sciences companies.



bpi**france**



About Advent France Biotechnology: www.adventFB.com

Advent France Biotechnology (AFB) is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects. AFB partners' unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company's growth. Created in 2016, AFB partners has made several European investments in France, Belgium, Spain and Ireland. AFB partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies. The operational team is managed by Alain Huriez and Matthieu Coutet. It has appointed a number of investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific and medical expertise.

AFB Seed Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.

Media contact:

NewCap

Nicolas Merigeau

Tel. : +33 (0)1 44 71 94 98

E-Mail : nmerigeau@newcap.fr